Ramipril Germed

Ramipril Germed may be available in the countries listed below.

Ingredient matches for Ramipril Germed

Ramipril

Ramipril is reported as an ingredient of Ramipril Germed in the following countries:

• Portugal

International Drug Name Search

Faslodex

Faslodex is a brand name of fulvestrant, approved by the FDA in the following formulation(s):

FASLODEX (fulvestrant - injectable; intramuscular)

• 
  Manufacturer: ASTRAZENECA
  
  Approval date: April 25, 2002
  
  Strength(s): 50MG/ML ^[RLD]

Has a generic version of Faslodex been approved?

No. There is currently no therapeutically equivalent version of Faslodex available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Faslodex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Formulation
  Patent 6,774,122
  Issued: August 10, 2004
  Inventor(s): John R; Evans & Rosalind U; Grundy
  Assignee(s): AstraZeneca AB
  The invention relates to a novel sustained release pharmaceutical formulation adapted for administration by injection containing the compound 7&agr;-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17&bgr;-diol, more particularly to a formulation adapted for administration by injection containing the compound 7&agr;-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17&bgr;-diol in solution in a ricinoleate vehicle which additionally comprises at least one alcohol and a non-aqueous ester solvent which is miscible in the ricinoleate vehicle.
  
  Patent expiration dates:
  
  
  • January 9, 2021
    
    ✓ 
    Patent use: TREATMENT OF HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY
  
  
  
  • July 9, 2021
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Formulation
  Patent 7,456,160
  Issued: November 25, 2008
  Inventor(s): Evans; John R & Grundy; Rosalind U
  Assignee(s): AstraZeneca AB
  The invention relates to a novel sustained release pharmaceutical formulation adapted for administration by injection containing the compound 7α-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17β-diol, more particularly to a formulation adapted for administration by injection containing the compound 7α-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17β-diol in solution in a ricinoleate vehicle which additionally comprises at least one alcohol and a non-aqueous ester solvent which is miscible in the ricinoleate vehicle.
  
  Patent expiration dates:
  
  
  • January 9, 2021
    
    ✓ 
    Patent use: TREATMENT OF HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY
  
  
  
  • July 9, 2021
    
    ✓ 
    Pediatric exclusivity
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • September 9, 2013 - CHANGE DOSAGE REGIMEN FROM 250MG TO 500MG
  
  
  • March 9, 2014 - PEDIATRIC EXCLUSIVITY
  
  
  • May 17, 2014 - SAFETY, EFFICACY AND PHARMACOKINETIC INFO FOR FASLODEX IN THE PEDIATRIC POPULATION, SPECIFICALLY FOR GIRLS WITH PROGRESSIVE PRECOCIOUS PUBERTY ASSOCIATED WITH MCCUNE-ALBRIGHT SYNDROME ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING
  
  
  • November 17, 2014 - PEDIATRIC EXCLUSIVITY
  
  

See also...

• Faslodex Consumer Information (Drugs.com)
• Faslodex Consumer Information (Wolters Kluwer)
• Faslodex Consumer Information (Cerner Multum)
• Faslodex Advanced Consumer Information (Micromedex)
• Faslodex AHFS DI Monographs (ASHP)
• Fulvestrant Consumer Information (Wolters Kluwer)
• Fulvestrant Consumer Information (Cerner Multum)
• Fulvestrant Intramuscular Advanced Consumer Information (Micromedex)
• Fulvestrant AHFS DI Monographs (ASHP)

Céfuroxime Zydus

Céfuroxime Zydus may be available in the countries listed below.

Ingredient matches for Céfuroxime Zydus

Cefuroxime

Cefuroxime axetil (a derivative of Cefuroxime) is reported as an ingredient of Céfuroxime Zydus in the following countries:

• France

International Drug Name Search

Raniberl

Raniberl may be available in the countries listed below.

Ingredient matches for Raniberl

Ranitidine

Ranitidine hydrochloride (a derivative of Ranitidine) is reported as an ingredient of Raniberl in the following countries:

• Bulgaria


• Estonia


• Latvia


• Lithuania


• Poland

International Drug Name Search

Padonil

Padonil may be available in the countries listed below.

Ingredient matches for Padonil

Glibenclamide

Glibenclamide is reported as an ingredient of Padonil in the following countries:

• Indonesia

International Drug Name Search

Motilium Pédiatrie

Motilium Pédiatrie may be available in the countries listed below.

Ingredient matches for Motilium Pédiatrie

Domperidone

Domperidone is reported as an ingredient of Motilium Pédiatrie in the following countries:

• Belgium

International Drug Name Search

Rifamicina-G

Rifamicina-G may be available in the countries listed below.

Ingredient matches for Rifamicina-G

Rifamycin

Rifamycin sodium salt (a derivative of Rifamycin) is reported as an ingredient of Rifamicina-G in the following countries:

• Argentina

International Drug Name Search

Gestageno

Gestageno may be available in the countries listed below.

Ingredient matches for Gestageno

Hydroxyprogesterone

Hydroxyprogesterone 17α-acetate (a derivative of Hydroxyprogesterone) is reported as an ingredient of Gestageno in the following countries:

• Argentina

International Drug Name Search